SS Innovations H1 2026 revenue rises to $25M
U.S. market clearance was anticipated in Q1 2027, dependent on the outcome of the review process.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
SS Innovations International, Inc. furnished its updated October 2026 company presentation for communications with shareholders and the investment community. It describes the SSi Mantra surgical-robotics platform and reports 244 systems installed and 14,503 multi-specialty surgeries as of September 28, 2026; the installed base spans 12 countries.
Revenue was $42,484,747 in 2025, compared with $20,649,528 in 2024; for the six months ended June 30, 2026, revenue was $25,041,075, compared with $15,120,915 a year earlier. For those six-month periods, gross margin was 49.6%, versus 46.3%, while net loss was $6,243,921, versus $5,938,044. Cash at June 30, 2026 was $22,295,891, including $8,648,461 of restricted cash.
As of September 28, 2026, 195 telesurgeries had been completed with the SSi Mantra; the presentation states India generated approximately 87% of 2025 revenue.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate point2025 revenue: $42,484,747, versus $20,649,528 in 2024.
- Moderate pointFirst-half 2026 revenue: $25,041,075, versus $15,120,915 in 2025.
Negative
- Minor pointFirst-half 2026 net loss: $6,243,921, versus $5,938,044 a year earlier.
Filing Explained
The presentation says the SSi Mantra is not approved for U.S. commercialization; FDA review is the current stage, a response to an FDA notice is listed for October 2026, and clearance is anticipated in the first quarter of 2027 subject to review, so U.S. entry is not yet cleared.
8-K Event Classification
Key Figures
Key Terms
Recurring revenue financial
510(k) regulatory
CE Marking regulatory
CDSCO regulatory
Degrees of Freedom technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much revenue did SSII report in 2025 and the first half of 2026?
How many SSi Mantra systems and surgeries did SSII report?
Has SSII's SSi Mantra received U.S. FDA clearance?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each Class | Trading Symbol | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As used in this Current Report on Form 8-K (this “Current Report”), the terms “SSi,” “the Company,” “we,” “us” and “our” refer to SS Innovations International, Inc. and its subsidiaries.
Item 7.01 Regulation FD Disclosure.
Included with this Current Report as Exhibit 99.1 is an updated October 2026 Company Presentation (the “Company Presentation”), which SSi intends to use in communications to shareholders and the investment community.
The information set forth in Item 7.01 of this Current Report and in the Company Presentation included as Exhibit 99.1 to this Current Report, are deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in Item 7.01 of this Current Report and in the Company Presentation included as Exhibit 99.1 to this Current Report, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
Forward-Looking Statements
This Current Report and the Company Presentation included as Exhibit 99.1 to this Current Report that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical statements of fact and statements regarding the Company’s intent, belief or expectations, including, but not limited to, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations and other statement that are predictive in nature. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SSi’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1* | October 2026 Company Presentation | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
| * | Furnished not filed |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: October 5, 2026 | SS INNOVATIONS INTERNATIONAL, INC. | |
| By: | /s/ Sudhir Srivastava | |
| Sudhir Srivastava, M.D. | ||
| Chairman and Chief Executive Officer | ||
2
Exhibit 99.1
We Build Advanced, Affordable and Accessible Surgical Robotic Solutions SS Innovations International, Inc. Company Presentation October 2026 Nasdaq: SSII
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 2 No Offering of Securities No offer is made by this Company Presentation (this "Presentation") to invest in SS Innovations International, Inc. (the "Company") or to purchase any of its securities. Any offer to make such an investment or purchase and such investment or purchase will be made only pursuant to definitive offering documentation furnished by the Company. Forward-Looking Statements This Presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by our forward-looking statements. Examples of forward-looking statements include statements regarding the benefits, uses and safety of our products, projected financial information, statements of our plans and objectives for future operations and statements concerning proposed new products and services. In some cases, you can identify forward-looking statements by the use of terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential" and other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements. Actual events or results may differ materially. We undertake no obligation to update any of the forward-looking statements after the date of this Presentation to conform them to actual results. Please refer to the risk factors described in the "Risk Factors" section and other sections included in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the SEC. Statistical and Other Industry and Market Data This Presentation includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties as well as our own estimates of potential market opportunities. All of the market data used in this Presentation involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, and management is responsible for the accuracy of such assumptions and data, no independent source has verified such assumptions. Disclaimers
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 3 Our Vision To continuously improve and deploy our technologically- advanced, cost-effective surgical robotic systems, while maintaining affordability and accessibility for the benefit of a larger segment of patients globally
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 4 Snapshot of SS Innovations • We develop innovative, differentiated surgical robotic technologies, highlighted by our: • Proprietary surgical robotic system, the SSi Mantra 3; • Comprehensive suite of surgical instruments, which support a variety of surgical procedures, including robotic cardiac surgery and robotic pediatric surgery; • AI- and XR-driven imaging, training and simulation platform; and • Pioneering telesurgery capabilities. • We are backed by a team of leading surgical robotics experts and seasoned medical technology executives. • We are a rapidly growing American company with Indian roots, expanding globally and preparing for a potential strategic entry into Europe and the United States. • Including the Company's strong foundational market of India, the SSi Mantra installed base currently spans 12 countries. 14,503 Multi-Specialty Surgeries 244 SSI Mantra Systems Installed 218 Hospitals 188 Validated Surgical Procedures 9 Surgical Specialities 755 Robotic Cardiac Surgeries 195 Telesurgeries 0 # of Significant Safety Events Reported Note: Data as of September 28, 2026 2022 Year of Commercialization
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 5 Snapshot of SS Innovations (Continued) Headquarters Gurugram, India Company Domicile Florida, USA Employees (June 30, 2026) 486 Year Merged with Avra Medical 2023 Year Uplisted to Nasdaq 2025 Ticker SSII Exchange Nasdaq-CM Shares Out (October 1, 2026) ~200 mm Recent Price (October 1, 2026) $2.75 Market Cap (October 1, 2026) ~$0.6 bn Insider Ownership (June 12, 2026) ~72% General Surgery 6,305 Urology 3,340 Gynecology 2,680 Colorectal 775 Cardiac 755 Gastrointestinal 350 Head & Neck 148 Thoracic 135 Breast and Plastic 15 14,503 Total Surgeries to Date1 1. Data as of September 28, 2026; 265 of these procedures were pediatric surgeries 105 224 As of 6/30/25 As of 6/30/26 Systems Installed (cumulative data) 5.9 20.6 42.5 15.1 25.0 2023 2024 2025 1H'25 1H'26 Revenue ($ millions) +113% +169% CAGR +66%
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 6 • Distinguished Leadership and Board with Proven Track Record in Surgical Robotics Technology • Large and Growing Total Addressable Market with Favorable Industry Tailwinds • Advanced, Cost-Efficient Surgical Robotics Platform – Clinically and Commercially Differentiated • Established Presence in India with Global Expansion Underway • Strong Sales Growth with an Increasing Mix of Recurring Consumables Revenue and Expanding Margins • Strategy to Deliver Long-Term, Sustainable Growth 1 2 3 4 5 Investment Highlights 6
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 7 Sudhir Srivastava, MD, Founder, Chairman & CEO • Robotic cardiac surgeon with 40+ years of experience • Pioneered many of the world's first robotic cardiac procedures • Performed numerous robotic cardiac surgeries and trained surgical teams worldwide • University of British Columbia, University of Chicago, Alliance Hospital • Owns ~108.6 million shares, or ~54% of SSII shares outstanding1 Distinguished Leadership and Board with Proven Track Record in Surgical Robotics Technology 1. As of 9/28/2026; Dr. Sudhir Srivastava's holdings exclude 4,872,287 shares issuable upon exercise of stock options with an average exercise price of $5.00 per share. Vishwajyoti Srivastava, MD, Chief Executive Officer, APAC & Board Member • Led the development of the OMNI 3D Medical Visualization system • Serves as the President of OMNI 3D HD to advance existing technological platform for availability in the global surgical and endoscopic marketplace • Previously served as the VP of Marketing and Technology at the International Centre for Robotic Surgery in New Delhi • Columbia University, Saint James School of Medicine Somashekhar SP, MD, Board Member • Robotic Surgeon • Global Director, Aster International Institute of Oncology Frederic Moll, MD, Vice-Chairman • Former Chief Development Officer, J&J Medical Devices • Founder, Intuitive Surgical, Hansen Medical, Auris Health • Co-Founder & Partner, Sonder Capital Management • Board Member, PROCEPT BioRobotics, Neptune Medical, Moon Surgical • Former Board Member, Shockwave Medical, Restoration Robotics, Intersect ENT • Owns ~20.8 million shares, or ~10% of SSII shares outstanding1 Barry Cohen, COO – Americas & Board Member • Co-Founder, CEO and Director, Avra Medical Robotics • Former Director and President, Synalloy Corp. • Former Chairman of the Board, Wolverine Technologies Tim Paul Adams, Board Member • Regional Operating Officer, Ascension • Former Regional CEO, Tenet Healthcare • Chairman, Tennessee Hospital Association Dr. Mylswamy Annadurai, Board Member • Former Director, Indian Space Research Organization
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 8 Large and Growing Addressable Market with Favorable Industry Drivers Accelerated Global Adoption of Robotic Surgery 1. Sourced from December 2025 Markets and Markets Surgical Robots Market Report 13.7 27.1 2025 2030E +14.7% CAGR Global Surgical Robotics Market1 (in USD billions) $ Benefits to Patients • Smaller incisions, reduced trauma, less blood loss • Less pain and discomfort, faster recovery time, minimal scarring • Enhanced outcomes and reduced risk of infection Benefits to Surgeons • Greater precision, magnified 3D vision, articulated dexterity • Reduced fatigue and minimized hand tremors (ergonomic systems) • Enhanced training pathways Benefits to Hospitals and Payers • Greater resource utilization • Improved economics - increased revenue and reduced costs • Lower complication rates and shorter stays Benefits of Robotic Surgery Underlying Drivers for Robotic-Assisted Surgery * Aging global population * Rising chronic diseases * Increasing demand from patients, surgeons and hospitals
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 9 Large and Growing Addressable Market with Favorable Industry Drivers Opportunity to Address Global Access ~11% ~89% Global Population1 (% of total population) Surgical Robotic Installed Base1 (% of total installations worldwide) >90% <10% 1. Estimates sourced from secondary market research Rest of World EU, US, Japan Rest of World EU, US, Japan SS Innovations aims to democratize access to surgical robotics in underserved regions of the world with its advanced and cost-effective SSi Mantra system. Greater than 90% of installed surgical robotic systems are located in the US, EU and Japan -- implying limited access to the rest of the world (~7.3 billion people).1 Traditional hurdle to global access: high cost of acquisition and implementation.
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 10 Large and Growing Addressable Market with Favorable Industry Drivers Significant Market Opportunity in Our Foundational Market of India 1. India data sourced from World Bank Group; US data sourced from the US Census Bureau. 2. India data sourced from INDHEAL; US data sourced from the American Hospital Association. 3. India data sourced from India Brand Equity Foundation report dated May 2026; US data sourced from OECD (Organization for Economic Cooperation and Development). 4. India data as of September 18, 2026, per Intuitive Surgical press release; US data as of June 30, 2026, per Intuitive Surgical 10-Q filing. 5. India data as of September 28, 2026; the SSi Mantra has not been approved for commercialization in the US market – it is currently under FDA review. India United States Population1 1.4 Billion 0.34 Billion Hospitals2 ~70,000 ~6,100 Hospital Beds (per 1,000 people)3 ~1.3 ~2.8 Da Vinci Robotic Systems Installed4 275 6,615 SSi Mantra Systems Installed5 225 * More than 2,000 surgeons in India have been trained in robotic-assisted surgery, including on the SSi Mantra.
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 11 Advanced, Cost-Efficient Surgical Robotics Platform SSi Mantra 3 1 2 3 1 Surgical Command Center Ergonomic open-faced console comprised of a pair of passive 3D glasses, a 3D 4k resolution monitor and a 2D touch monitor for system controls 2 Patient-Side Robotic Arm Carts Modular robotic arms mounted on individual carts with the option of using 3, 4 or 5 robotic arm configurations 3 Vision Cart 3D 4K resolution monitor, identical to the surgeon's console, for OR staff. Also houses the control system for the articulating endoscope and camera and pre- operative guidance software 4 Instrument and Accessories Comprehensive suite of stapling, energy and core instrumentation for the surgical system under the brand name SSi Mudra 4
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 12 Advanced, Cost-Efficient Surgical Robotics Platform SSi Mantra 3 – Surgical Command Center Ergonomic Open-Faced Console Large 3D 4K Monitor Large 2D Touch Monitor for System Controls and DICOM access Lightweight Magnetic Hand Controls Design Head Tracking Safety Feature Digital Ergonomics Control Tele Surgery and Tele Proctoring Enabled
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 13 Advanced, Cost-Efficient Surgical Robotics Platform SSi Mantra 3 – Patient Side Robotic Arm Carts Modular Robotic Carts Freedom of Patient Docking 3/4/5 Patient Cart Connectivity Absolute Stability Parking Locks Smaller Individual Cart Footprint Advanced Touch Screen Controls
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 14 Advanced, Cost-Efficient Surgical Robotics Platform SSi Mantra 3 – Vision Cart Large 3D 4K Monitor for Operating Room Staff Inbuilt Multimedia Recording, Playback and Streaming 3D 4k ICG Camera System with 0- and 30-degree Endoscope Pre-Operative Guidance Software UPS Backup E-Stop Safety Features Standard 5 Robotic Arms Connectivity Control Box
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 15 Advanced, Cost-Efficient Surgical Robotics Platform SSi Mudra – Multi Specialty Robotic Instruments 7 Degrees of Freedom Articulating Robotic Instruments 10 Use Life Cycle per Instrument 20+ Cardiac Specialty Instruments Only company in the world actively advocating for robotic cardiac surgery Untapped market potential in automated coronary artery bypass surgery 400+ complex robotic cardiac surgeries performed with the SSi Mantra 40+ Types of Instruments Novel Instrument: Automated Coronary Anastomotic Connector1 Novel Instrument: Multi-Fire Clip Applier2 Advanced Instruments: Selicut Harmonic Advanced Instruments: ExpertSeal Vessel Sealer Advanced Instruments: Anastoflex Stapler 1. Includes instruments under development. 2. Under development. 1 1 The Company has developed six new 5-millimeter surgical robotic instruments for clinical use across multiple specialties, including pediatric, cardiac, and head and neck surgery, among other procedures involving smaller anatomical structures.
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 16 Advanced, Cost-Efficient Surgical Robotics Platform SSi Maya – Enhancing Surgical Capabilities with Mixed Reality and AI Enabled Technologies SSi Guru XR Tele Proctoring System • Mixed Reality Headset • Portable 3D Surgery Viewer • Interactive Virtual Screens • CDSCO Approved • Virtual Tele Illustration Feature • Proctored over 1,200 miles under 400 ms latency AR Smart Glasses1 3D Visualization System • 3D HD 1080p vision • Variable IPD adjustments • Direct from endoscope video signal processing • IMU based head tracking Cognitive Skill Simulator1 A different approach to train surgeons • Overlaid instruments tracking • Guided procedure steps • Trains cognition and muscle memory • Enhancing motor skills through repetition • Console and VR based learning system Mixed reality-powered and AI-enabled technologies for better training, visualization, and simulation for the entire surgical team. 1. In development
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 17 Advanced, Cost-Efficient Surgical Robotics Platform Supported by the SS International Centre for Robotics Surgery ("SSICRS") SS International Centre for Robotics Surgery • A premier educational institute for robotic-assisted surgical training • Subsidiary of SS Innovations • Located at the Company's headquarters in Gurugram, India World Class Training Center • Modern lecture halls and state-of-the-art labs • Top-tier faculty, including renowned international surgeons • Multi-specialty training leverages on-site SSi Mantra systems • Balance of hands-on learning and classroom theory • Tele-proctoring and engineering-integrated learning In July 2026, SSICRS graduated its first class in a specialized training course designed to provide surgeons with hands-on learning in robotic- assisted cardiac surgery. SSICRS will offer training across multiple procedure types, leveraging the SSi Mantra platform as a training tool.
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 18 Advanced, Cost-Efficient Surgical Robotics Platform Pioneering Telesurgery Capabilities and Mobile Robotic Telesurgery Unit First system approved for telesurgery in India.1 We enhance remote surgical access and empower underserved communities through telesurgery, surgical education, mentoring, and real-time data insights. 1. CDSCO approval (India) 2. As of 9/28/26 3. Communication line distance IRCAD HQ Strasbourg, France Sri Aurobindo IMS Indore, India 4,000+ miles Jul 2025 Perth, Australia Sri Aurobindo IMS Indore, India 6,250+ miles3 May 2026 Georgetown, Guyana IRCAD Indore, India 12,500+ miles3 May 2026 195 telesurgeries have been completed with the SSi Mantra surgical robotic system2 March 2026 - SSi Mantra approved for telesurgery in Indonesia and the Philippines Bucaramanga, Columbia Mohak Bariatrics Indore, India 13,600+ miles3 July 2026 World's Longest-Distance Robotic Telesurgery
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 19 Advanced, Cost-Efficient Surgical Robotics Platform The SSi MantrAsana Tele-Surgeon Console Facilitates Telesurgery from "Anywhere" Compact Self- Contained Chair Inbuilt Electronics Magnetic Sensor- Based Controls Lightweight Glasses Magnified Three- Dimensional View SSi MantrAsana Tele-Surgeon Console Enables Portability Requires Less Space Facilitates Telesurgery from Physician's Offices and other Locations with Limited Working Space
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 20 Established Presence in India with Global Expansion Underway World-Class R&D and Manufacturing Facilities to Support Growth and Cost Efficiency R&D, Manufacturing, Assembly, and Operations in Gurgaon, Delhi National Capital Region (India) Proximity to New Delhi International airport with excellent connectivity with all parts of the world ~91,000 sq ft space spread over three floors as of June 30, 2026 20 Systems per month Current Production Capacity 486 employees as of June 30, 2026 Plan to expand manufacturing to match growth 91,000 sq ft FACILITY
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 21 105 224 As of 6/30/25 As of 6/30/26 Cumulative Installed Base 4,657 12,272 As of 6/30/25 As of 6/30/26 Completed Procedures Installed base Overview of Installed Base +113% +164% Academic center Established Presence in India with Global Expansion Underway SSi Mantra 3 Is Demonstrating Rapid Adoption Across Various Geographies 244 as of 9/28/26 14,503 as of 9/28/26
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 22 EU CE Anticipated Q4 '26 Guyana 2026 US FDA Anticipated Q1 '27 Established Presence in India with Global Expansion Underway Global Expansion - Regulatory Approvals India CDSCO 2023 Colombia 2025 Indonesia 2024 Guatemala 2023 In 2025, SS Innovations generated approximately 87% of its revenue from India. We expect the percentage of total revenue coming from the rest of the world to significantly expand over time. Oman 2025 Kenya 2026 Australia, Brunei, Laos, Morrocco, Thailand, Vietnam Anticipated 2026 Philippines 2025 Ukraine 2025 Iraq 2025 UAE 2025 Ecuador 2024 Sri Lanka 2026 Nepal 2026 Chile, Nigeria, Mauritius Approval Not Required
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 23 Route of Conformity to Notified body Certification EN ISO 13485 Completed Stage 1 Audit Desktop Q4 2025 Stage 2 Audit On Site Q2 2026 CE Marking Q4 20262 Initial Review - Application and Technical File March 2025 Notified body - Szutest, Germany Current Stage Technical File Review Q3 2026 EU CE Mark FDA Q Sub 2024 510(k) Technical Dossier Preparation1 510(k) Submitted Multi-Specialty Indications Q4 2025 FDA Review / Market Clearance Q1 20272 Current Stage US FDA AINN Received April 8, 2026 180 days to respond Clinical for Chole Indication and HF trials Q3 2026 Response to AINN October 2026 Established Presence in India with Global Expansion Underway Estimated Regulatory Timelines 1. Human factor validation in the US 2. Dependent on the outcome of the review process
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 24 85% 15% $42.5 mm Revenue 2025 Strong Sales Growth with an Increasing Mix of Recurring Consumables Revenue and Expanding Margins $5.9 $20.6 $42.5 2023 2024 2025 Revenue ($ millions) +251% Gross Margin (%) 12.35% 40.93% 46.00% 2023 2024 2025 +2,858 bps +507 bps Revenue Mix (%) Systems Capital Sales Recurring 1 +106% 1. Recurring revenue defined as systems on rental / lease, instruments and consumables sales and maintenance service fees
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 25 38 56 1H'25 1H'26 SSi Mantra Installations (# of systems) First Half 2026 – Robust Growth in Revenue and SSi Mantra Installations and Procedures $15.1 $25.0 1H'25 1H'26 Revenue ($ millions) +66% +47% 1,861 4,387 1H'25 1H'26 SSi Mantra Procedures (# of surgeries) +136%
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 26 Growth Strategy Continuously Improve and Innovate our top-tier robotics platform through New Product Development and Enhanced Technology. Maintain Stronghold in India, grow in Select Underserved Countries with low penetration and cost barriers, and pursue Established Markets. In the United States, after FDA approval, focus on ASCs and Smaller Hospitals while leveraging the SSi Mantra's differentiated Cardiac surgery capabilities. Focus on Large Multi-Specialty Hospitals • Secure Initial Placements • Expand # of Physicians using Mantra 3 • Increase System Utilization at Each Hospital • Place Additional Systems at Each Hospital (Go Deeper) Target Leading Surgeons and Thought Leaders to Raise Awareness and Encourage Widespread Adoption • Indian Medical Advisory Board • International Advisory Board • Medical Conferences • Robotic Surgery Training Programs • Strategic Partners (e.g., Johns Hopkins) Platform Value • Advanced Technology • Lower Cost • Ease of Training • Improved Patient Outcomes • Differentiated Features (e.g., Cardiac)
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 27 Appendix
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 28 Financial Summary SS Innovations Twelve Months Ended Six Months Ended Three Months Ended Statement of Operations (in USD) Dec. 31, 2023 Dec. 31, 2024 Dec. 31, 2025 June 30, 2025 June 30, 2026 June 30, 2025 June 30, 2026 Revenue 5,875,314 20,649,528 42,484,747 15,120,915 25,041,075 10,000,305 13,939,709 Gross Profit 725,528 8,452,366 19,544,255 7,002,266 12,428,171 5,915,058 7,100,950 Gross margin 12.3% 40.9% 46.0% 46.3% 49.6% 59.1% 50.9% Operating (loss) income (20,273,984) (18,975,962) (8,194,034) (5,623,766) (5,896,932) 97,014 (2,271,354) Net (loss) income (20,878,292) (19,151,197) (8,160,947) (5,938,044) (6,243,921) (256,691) (2,661,350) Diluted EPS $(0.14) $(0.11) $(0.06) $(0.03) $(0.03) $(0.00) $(0.01) Diluted shares 152,069,825 181,203,673 198,699,461 195,502,268 207,369,897 202,835,698 209,422,550 Balance Sheet (in USD) June 30, 2026 Cash1 22,295,891 Current assets 71,453,952 Total assets 96,982,013 Current liabilities 31,891,727 Long term debt - Total stockholders' equity 53,401,223 1. Includes restricted cash of $8,648,461
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 29 Summary of SSi Mantra Installations 3 15 47 103 2022 2023 2024 2025 3 18 65 168 2022 2023 2024 2025 Year # Growth 2022 3 - 2023 15 400% 2024 47 213% 2025 103 119% Year # Growth 2022 3 - 2023 18 500% 2024 65 261% 2025 168 158% Annual Installations Cumulative Installations1 1At end of period Year # Growth Q1'24 9 - Q2'24 10 - Q3'24 6 - Q4'24 22 - Q1'25 15 67% Q2'25 23 130% Q3'25 27 350% Q4'25 38 73% Q1'26 26 73% Q2'26 30 30% Quarterly Installations 9 10 6 22 15 23 27 38 26 30 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Note: all growth % figures are year over year comparisons
© 2026 SS INNOVATIONS INTERNATIONAL, INC. 30 www.ssinnovations.com investors@ssinnovations.org Investor Contact: Kalle Ahl, CFA (303) 953-9878 kalle.ahl@theequitygroup.com